Heart Beat: June 2023


New Drug an Option for Statin-Intolerant Patients

Statins are the first choice of drugs to lower “bad” LDL cholesterol and the risk of cardiovascular events that accompanies it. But a certain percentage of patients suffer muscle-related side effects from statins and discontinue taking them. Results of a 14,000-patient international clinical trial known as CLEAR Outcomes, presented at the American College of Cardiology (ACC) Annual Scientific Sessions and simultaneously published online March 4 in the New England Journal of Medicine, showed that bempedoic acid (Nexletol™) may be an effective substitute in these individuals. In this trial, bempedoic acid lowered LDL cholesterol by 21% and the risk of a major adverse cardiovascular event (MACE), a composite of cardiovascular death, heart attack, stroke and revascularization, by 19% in statin-intolerant patients. Because bempedoic acid is activated in the liver but not in the peripheral tissues, it causes few muscle-related events. In fact, the percentage of patients reporting muscle issues from taking bempedoic acid was almost identical to that of placebo takers.

To continue reading this article or issue you must be a paid subscriber. Sign in

Subscribe to Heart Advisor

Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access